Palvella Therapeutics (PI6) Ratios
0 Followers
Palvella Therapeutics Ratios
DE:PI6's free cash flow for Q3 2026 was $-14.43M. For the 2026 fiscal year, DE:PI6's free cash flow was increased by $0.00 and operating cash flow was $-14.43M. See a summary of the company’s cash flow.
| Ratios | Mar 26 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.20 | 7.33 | 3.20 | 2.86 | 2.52 |
| Quick Ratio | 5.20 | 7.33 | 3.20 | 2.86 | 2.52 |
| Cash Ratio | 5.11 | 6.94 | 3.11 | 2.78 | 2.33 |
| Solvency Ratio | -1.32 | -0.68 | 1.64 | -0.77 | -0.42 |
| Operating Cash Flow Ratio | -2.20 | -0.90 | -5.81 | -2.57 | -0.15 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | -7.30 |
| Net Current Asset Value | $ 27.41M | $ 62.61M | $ -3.88M | $ -23.17M | $ 24.82M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.00 | 0.00 | 0.10 |
| Debt-to-Equity Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.29 |
| Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.23 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.13 | 1.41 | -1.95 | -0.71 | 3.03 |
| Debt Service Coverage Ratio | -6.17 | -3.04 | 0.00 | 0.00 | -41.34 |
| Interest Coverage Ratio | -6.63 | -3.26 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| Interest Debt Per Share | 0.57 | 1.94 | 0.00 | 0.00 | 18.45 |
| Net Debt to EBITDA | 1.60 | 6.37 | -0.39 | 0.53 | 2.37 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 89.27% | 92.46% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | -128.47% | -145.58% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | -117.74% | -138.04% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | -167.84% | -164.97% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | -128.47% | -145.58% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | -128.47% | -145.58% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | -128.47% | -145.58% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 108.06% | 123.69% | -157.48% | 76.54% | 88.24% |
| Return on Assets (ROA) | -70.04% | -19.76% | 247.63% | -201.39% | -29.79% |
| Return on Equity (ROE) | -149.07% | -27.85% | -481.73% | 143.60% | -90.12% |
| Return on Capital Employed (ROCE) | -80.06% | -18.50% | -228.78% | -404.71% | -50.32% |
| Return on Invested Capital (ROIC) | -79.73% | -18.50% | -228.78% | -404.71% | -49.81% |
| Return on Tangible Assets | -70.04% | -19.76% | 247.63% | -201.39% | -29.79% |
| Earnings Yield | -3.54% | -65.27% | 86.71% | -210.40% | -333.46% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 9.48 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.87 | 0.28 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 1.36 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 1.57 | 0.20 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.59 | 0.48 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -417.65 | -1288.49 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 38.49 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 417.65 | 1326.98 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 38.49 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.22 | -4.87 | -10.81 | -15.95 | -9.49 |
| Free Cash Flow Per Share | -2.22 | -4.87 | -10.81 | -15.95 | -10.67 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -8.07 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -8.07 |
| Operating Cash Flow Coverage Ratio | -39.50 | 0.00 | 0.00 | 0.00 | -0.51 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | -0.57 | -0.24 |
| Free Cash Flow Yield | -2.12% | -40.58% | -63.57% | -93.83% | -62.77% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -28.21 | -1.53 | 1.15 | -0.48 | -0.30 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.61 | 0.44 |
| Price-to-Book (P/B) Ratio | 42.09 | 0.43 | -5.56 | -0.68 | 0.27 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -47.10 | -2.46 | -1.57 | -1.07 | -1.59 |
| Price-to-Operating Cash Flow Ratio | -47.10 | -2.46 | -1.57 | -1.07 | -1.79 |
| Price-to-Earnings Growth (PEG) Ratio | 0.54 | 0.01 | -0.01 | 0.01 | 0.00 |
| Enterprise Value Multiple | -31.21 | 4.34 | 0.76 | 0.01 | 2.06 |
| Enterprise Value | 1.12B | -56.89M | 14.21M | -237.02K | -89.16M |
| EV to EBITDA | -31.21 | 4.34 | 0.76 | 0.01 | 2.06 |
| EV to Sales | 0.00 | 0.00 | 0.00 | -0.01 | -2.84 |
| EV to Free Cash Flow | -44.80 | 5.25 | -1.04 | 0.02 | 10.36 |
| EV to Operating Cash Flow | -44.80 | 5.25 | -1.04 | 0.02 | 11.64 |
| Tangible Book Value Per Share | 2.49 | 28.13 | -3.06 | -24.91 | 62.91 |
| Shareholders’ Equity Per Share | 2.49 | 28.13 | -3.06 | -24.91 | 62.91 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 27.84 | 38.94 |
| Net Income Per Share | -3.71 | -7.83 | 14.74 | -35.77 | -56.69 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.16 | 1.33 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 1.94 | 2.04 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 |
| Income Quality | 0.60 | 0.62 | -0.73 | 0.54 | 0.17 |
Currency in USD
